

Respiratory Syncytial Virus Seasonality: A Global Overview

Pablo Obando-Pacheco,^{1,2} Antonio José Justicia-Grande,^{1,2} Irene Rivero-Calle,^{1,2} Carmen Rodríguez-Tenreiro,^{1,2} Peter Sly,³ Octavio Ramilo,^{4,7,8} Asunción Mejías,^{4,7,8} Eugenio Baraldi,^{4,9} Nikolaos G. Papadopoulos,^{4,11,12} Harish Nair,^{4,13} Marta C. Nunes,^{4,15,16} Leyla Kragten-Tabatabaie,^{4,5} Terho Heikkinen,^{4,17} Anne Greenough,^{4,14,20,21} Renato T. Stein,^{4,18} Paolo Manzoni,^{4,10} Louis Bont,^{4,6,19} and Federico Martinón-Torres^{1,2,4}

¹Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago, and ²GENVIP Research Group, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Galicia, Spain; ³Children's Lung Environment and Asthma Research, Child Health Research Centre, University of Queensland, Brisbane, Queensland, Australia; ⁴Respiratory syncytial virus network (ReSViNET), ⁵Julius Clinical, University Medical Center Utrecht, Zeist, and ⁶Department of Pediatrics, University Medical Center Utrecht, The Netherlands; ⁷Department of Pediatrics, Division of Infectious Diseases, Ohio State University, and ⁸Center for Vaccines and Immunity at Nationwide Children's Hospital, Ohio State University, Columbus; ⁹Women's and Children's Health Department, University of Padova and ¹⁰Neonatology and Neonatal Intensive Care Unit, S Anna Hospital, Torino, Italy; ¹¹Department of Allergy, 2nd Pediatric Clinic, University of Athens, Greece; ¹²Division of Infection, Immunity & Respiratory Medicine, University of Manchester, ¹³Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, and ¹⁴MRC & Asthma UK Centre for Allergic Mechanisms in Asthma, King's College London; ¹⁵Respiratory and Meningeal Pathogens Research Unit, and ¹⁶Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of Witwatersrand, Johannesburg, South Africa; ¹⁷Department of Pediatrics, University of Turku and Turku University Hospital, Finland; and ¹⁸Pediatric Pulmonology Unit, Pontifícia Universidade Católica RS, Porto Alegre, Brazil; ¹⁹Laboratory of Translational Immunology, University Medical Center Utrecht, The Netherlands; ²⁰Department of Women and Children's Health, School of Life Course Sciences; ²¹Faculty of Life Sciences and Medicine, King's College London.

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children. By the age of 1 year, 60%–70% of children have been infected by RSV. In addition, early-life RSV infection is associated with the development of recurrent wheezing and asthma in infancy and childhood. The need for precise epidemiologic data regarding RSV as a worldwide pathogen has been growing steadily as novel RSV therapeutics are reaching the final stages of development. To optimize the prevention, diagnosis, and treatment of RSV infection in a timely manner, knowledge about the differences in the timing of the RSV epidemics worldwide is needed. Previous analyses, based on literature reviews of individual reports obtained from medical databases, have failed to provide global country seasonality patterns. Until recently, only certain countries have been recording RSV incidence through their own surveillance systems. This analysis was based on national RSV surveillance reports and medical databases from 27 countries worldwide. This is the first study to use original-source, high-quality surveillance data to establish a global, robust, and homogeneous report on global country-specific RSV seasonality.

Keywords. respiratory syncytial virus (RSV); RSV seasonality; RSV epidemiology; respiratory infections; RSV surveillance.

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children. By the age of 1 year, 60–70% of children have been infected by RSV (2%–3% of whom are hospitalized), and almost all children have been infected by 2 years of age [1]. This virus is estimated to cause approximately 33.8 million new episodes of acute lower respiratory infections annually in children aged <5 years worldwide, resulting in 3.2 million hospital admissions and 59 600 in-hospital deaths in children aged <5 years in 2015 [2]. In addition, early-life RSV infection is associated with the development of recurrent wheezing and asthma in infancy and childhood [3].

The need for precise epidemiologic data regarding RSV as a worldwide pathogen has been growing steadily as novel vaccines and molecules for the prevention and treatment of RSV

infections are reaching the final stages of development [4]. To establish timely countermeasures to control the pathogen, information about the different epidemic waves of the virus is needed [4]. Many Western countries have included detection of RSV as part of their influenza surveillance system, especially because it has been noted that its circulation generally predates that of the influenza virus by 6–8 weeks. Nevertheless, many countries have not implemented a routine surveillance system for RSV, or they have done so only in certain regions or even only in specific medical facilities. The aim of this report is to provide an overview of RSV seasonality in 27 countries across the world.

METHODS

We surveyed 27 countries distributed among 9 predefined geographical areas for epidemiological data (Figure 1).

Selection Strategy

Selection of the regions studied was done through a 2-searches approximation conducted between June 2016 and September 2017. A first general search was conducted in Google to detect countries with official surveillance programs producing accessible reports containing information on RSV seasonality. The

Received 31 October 2017; editorial decision 22 January 2018; accepted 24 January 2018; published online January 30, 2018.

Correspondence: F. Martinón Torres, MD, PhD, Head of Pediatrics and Director of Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago de Compostela, A Choupana, 15706 Santiago de Compostela, Spain (federico.martinon.torres@sergas.es).

The Journal of Infectious Diseases® 2018;217:1356–64

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/infdis/jiy056




Figure 1. Countries covered by the review

search terms used were “RSV” or “respiratory syncytial virus” or “influenza” plus “surveillance”. A total of 19 countries were selected. Most surveillance systems had RSV-specific data available from laboratory detections, but for France we used syndromic “bronchiolitis” data. To complement and compare the information obtained from the official reports and to increase the information gathered in poorly covered areas, a literature review was performed in PubMed of articles published between 1990 and 2017. The keywords used were “respiratory virus” OR “respiratory syncytial virus” OR “RSV” in combination with “seasonality” OR “surveillance.” Only studies reflecting specific information on RSV seasonality (ie, start, end, peak, or duration of the RSV season) were extracted. Eight new countries were added to the initial survey to increase the total number of countries studied to the final figure of 27. Only records written in English, Spanish, German, French, and Portuguese were included in this study.

Information Retrieved

Variables recovered from the different reports were as follows: start and end of the RSV season (in epidemiological week or month if the specific week was not available), peak of RSV activity (in epidemiological week or month if the specific week was not available), duration of the seasons, presence of official RSV surveillance program, period studied, region variability, and usage of laboratory detection. Data for each country were collected by 2 independent investigators from the ReSVinet (Respiratory Syncytial Virus Network)/GENVIP (Genetics, Vaccines, Infectious Diseases and Pediatrics) research groups.

We relied on data provided by official national reports to establish the start and end of the RSV season, whenever available. In Europe, the first reports with official data about RSV detection are available as early as 1995 for Finland, 1996 for

Germany, and 1998 for Belgium, and as late as the end of the 2000s for Spain and the United Kingdom. In South and Central America, the earliest reports are found in 2009 for Brazil and Argentina. North America RSV official seasonality reports date as early as 1983. With the exception of New Zealand, which has provided information regarding RSV since 1997, the rest of the countries studied have accessible data on RSV surveillance starting from the late 2000s. We recovered information from official surveillance organization reports from 2010 onward whenever possible.

In countries with no official sources on RSV epidemiology and disease burden, information was systematically extracted from the best reliable medical source at our disposal. Initially, World Health Organization (WHO) and US Centers for Disease Control and Prevention (CDC) reports for each of the countries were reviewed, then local and multicenter publications assessing several consecutive RSV seasons were also reviewed, and finally a review of published articles documenting RSV burden limited to a local area or a group of hospitals were used, if no better sources were available. For those countries with no precise information regarding exact timing and duration of RSV season, the onset of RSV season was defined as the first 2 consecutive weeks when $\geq 10\%$ of the total tested samples for respiratory pathogens were positive for RSV. The end of the RSV season was defined similarly as when the proportion of positive RSV tests fell below 10% for 2 consecutive weeks.

RESULTS

Although there were major differences among the 27 countries studied, seasonal RSV epidemics within each individual country were consistent over time. We found that even when global trends were documented and usually repeated over seasons, some variations between different years were observed. Even

when most countries included ($n = 19/27$) had official surveillance systems, information devoted to RSV was usually scarce and embedded within influenza surveillance reports (Figure 2). Almost every sentinel program detected RSV through laboratory methods (excluding France), but almost no information regarding the specifics of the microbiological test used was available in the majority of the reports.

Table 1 and **Figure 2** summarize the RSV seasonality data per country, and a detailed version of Europe is presented in **Figure 3**.

Globally, RSV epidemics started in the south and moved to the north. We found that the RSV wave started in most countries in the Southern Hemisphere between March and June and in countries in the Northern Hemisphere between September and December [5–7]. Decrease in RSV activity was observed from August to October in the Southern Hemisphere and from February to May in the Northern Hemisphere [5–7]. Regarding duration, most countries in both hemispheres had seasons that lasted 5–6 months in total. Although this was the general rule, shorter seasons were seen in Spain (3–5 mo) [8], United Kingdom (3–4 mo) [9], and Israel (4 mo) [10] in the Northern Hemisphere, whereas in the Southern Hemisphere, RSV activity in Australia [11] usually lasts approximately 4 months. An exception to this pattern was seen in countries with humid or rainy seasons, particularly those near the equatorial area like Mozambique [12, 13] and Malaysia [14], where RSV tended to linger longer, lasting up to 10 months.

The seasonality was fairly consistent within most regions, although we observed variations from year to year. These variations were independent of the hemisphere, and in the majority of countries, the start, end, and/or peak of RSV activity usually differed by only 1–3 weeks from season to season; however, most countries showed major variations of 1 month at least once during the studied periods. Curiously, these major variations were less appreciated in the regions where no surveillance system was established (probably related to the scarce sources of information found). Despite the straightforward trends described, there were some countries that presented irregular patterns. In Germany [15], 2 differential patterns of RSV seasonality have been detected: an early season starting in October–November and finishing in March–April and a late season starting in December and finishing in May, with both seasons having a similar duration. Respiratory syncytial virus infections in Finland, according to the data gathered from the literature review, follow a 2-year cycle [16, 17]. A small epidemic in the spring of every odd-numbered year is followed by a major epidemic that starts in November–December and extends to the next spring. Seasonality also follows a distinctive pattern in Mexico [18]. A 2-season year is followed by a milder year, where the outbreak starts in spring and activity is maintained almost all year round with no clear peaks. Intracountry differences in seasonality were noted, especially in countries with large territories and different regional climatic regions, such as Brazil [19], the

United States [20], and Australia [11, 21–23]. Additional details and references on seasonality of RSV by region are available in the **Supplementary Material**.

DISCUSSION

To our knowledge, this is the first study to use original-source, high-quality data relying predominantly on the official information gathered by the different surveillance networks to establish a global report on country-specific RSV seasonality, allowing the typical worldwide distribution of RSV seasonality to be observed at a glance. We have included a wide selection of information retrieved not only from research studies but also, and more important, from the actual surveillance systems in the different countries. This method allowed us to obtain better distribution and homogeneity of the information acquired than did studies based exclusively on literature reviews. Those earlier studies usually recorded information in hospital settings, reporting data from few regions or centers and thus failing to establish global country seasonality patterns. Furthermore, we could not find in the literature any other review that reflects the specific ranges in which seasons and RSV peaks of activity vary during the periods studied. Many other original papers are based on regional or single-country data, and they have been useful for analyzing the circulation of RSV in their respective regions [6, 12–14, 16, 17, 19, 22–48].

The first global RSV seasonality study found in the literature was conducted in 2002 by Stensballe et al [5]. The authors reported different patterns for the Northern and Southern Hemispheres and the equatorial region in a city-based format, relying on information provided by medical databases. Haynes et al [6] worked in conjunction with the CDC Global Disease Detection Centers to investigate different trends in low- and middle-income countries. They analyzed the data in conjunction with the climate patterns. The largest study in the literature was carried out by Bloom-Feshbach et al [7], which reported information from 137 global locations based on a literature review, electronic sources, and the WHO surveillance system FluNet. Their study showed seasonal patterns of RSV similar to those in this study, with temperate locations of the Northern and Southern Hemispheres characterized by focused peaks of activity during their respective winters and a wide range of variability in the timing and duration of epidemics in the tropics.

In regard to weather conditions, the general rule in temperate climate regions, such as those of Europe or North America, is that RSV activity follows the decrease in temperature. Exceptions were observed in equatorial countries and tropical areas with high humidity, such as the Philippines and Mozambique, where viral circulation is seen primarily during the rainy season, although residual activity is seen throughout the year [5–7].

This study is meant to serve as a general guide for RSV seasonality, not only to provide general knowledge about the




Figure 2. Country-specific respiratory syncytial virus (RSV) epidemiology. Some countries have >1 peak month because RSV shows activity in different months every season. Respiratory syncytial virus usually travels from the south to the north, starting between March and June in most countries in the Southern Hemisphere and between September and December in countries in the Northern Hemisphere. Humid countries have their seasonal wave during the rainy season.

epidemiology of the virus but also to serve as a basis for actual preventive and therapeutic strategies against RSV using established prophylaxis measures and/or those about to be released

to the market. Even though we have highlighted the consistency between seasons and we expect this information to be very useful, it should be considered as a complement for the

Table 1. RSV Seasonality Description Per Country

Country	Start (season week)	Peak (season week)	End (season week)	Season length (weeks)	Period studied	Region variability
EUROPE						
Belgium	39–43	49–50	7–13	18–22	2004–2014	No
France (official, syndromic-based)	35–37	48–52	10–14	25–31	2011–2017	No
France (unofficial RSV surveillance)	October–November	December	February–March	20–24	2011–2014	No data
Finland	50–1**	7–10	17–20	19–21	2010–2015	Yes
Germany	Early 40–47	52	11–15	19–21	2010–2017	No
	Late 50–52	52–16*	18	16–22		
Greece	December	February	April/May	20	1999–2013	No data
Italy	October	January/February	April/May	24–30	2000–2014	Yes
The Netherlands	45–49	51–8*	15–17	19–23	2010–2016	No data
Spain	44–45	50–52	6–12	12–19	2010–2017	No
United Kingdom	43–45	49–52	4–6	11–15	2010–2016	No
AMERICA						
North America						
Canada	46–49	52–8*	15–18	20–22	2012–2017	Yes
United States	44–46	52–4*	12–14	21–23	2011–2017	Yes
Central America						
Guatemala	16–23	30–34	43–47	25–31	2015–2017	No
Mexico	1	17–18	17–20	17–20	2012–2015	No data
	35–39	37–45	46–47	7–12		
	13–16	20–30	29–42	16–36		
South America						
Argentina	16–19	24–27	35–40	20–22	2011–2017	No
Brazil	7–11	14–19	29–31	19–24	2009–2017	Yes
Chile	19–22	26–32	36–41	16–20	2011–2017	Yes
SOUTHERN AFRICA						
Mozambique	October	March	May	16–40	1998–2000	No data
South Africa	2–9	10–18	19–33	19–33	2009–2016	No
OCEANIA						
Australia	19–23	27–31	34–38	14–16	2009–2016	Yes
New Zealand	18–20	29–34	35–39	19–23	2010–2015	No
ASIA						
Middle East						
Israel	44–49	51–3*	5–9	13–18	2005–2017	No
Southern Asia						
Malaysia	July	September–December	March	36	1982–2008	No
Philippines	October	November–December	February	20	2010–2013	Yes
Thailand	April–May	September	November	24	2005–2011	No
East Asia						
China	November	December–February	April	24	2010–2015	Yes
Japan	30–45	41–50	45–9**	14–27	2010–2017	No data
South Korea	August–October	Mid-October–November	December	14–20	2008–2016	No data

Each range represents the earliest and the latest epidemiological week or month were the start, end or peak was observed during the seasons studied per country. Duration is presented as a range where the shortest and the longest epidemic of the seasons studied per country are shown.

*Depending on the season, peak is seen in the previous epidemiological year or the next.

**Depending on the season, the start or end of the epidemic is seen in the previous epidemiological year or the next.

actual information gathered in real time by the current surveillance systems. Major variations of a month or more that could make a preventive measure useless do occur occasionally. Therefore, we propose that the best approach to predict RSV outbreaks is to construct a robust, homogeneous, active, and global surveillance program with real-time data to help predict the epidemiologic waves in a timely fashion. A number

of countries have been recording RSV cases through their own surveillance systems for some years now. These countries, however, are a minority, and most of them only include RSV surveillance as a secondary detection alongside other surveillance campaigns (ie, influenza virus and bronchiolitis surveillance), with scarce information regarding RSV. In areas without official surveillance systems, one has to rely on single




Figure 3. Country-specific respiratory syncytial virus (RSV) epidemiology in Europe. Respiratory syncytial virus usually travels from the south to the north and from the west to the east, showing activity in the continent from October to May in some countries. Peak activity is usually seen in winter for most the countries, except for the most northern countries, where high activity is seen in the beginning of spring.

or multicenter studies done by various research groups. To this respect, WHO, through the Global Influenza Surveillance and Response System, is in the process of implementing a pilot

of RSV surveillance based on the influenza surveillance platform, with 14 countries selected to cover each of the WHO regions [49].

Our approach also allowed us to study the seasonality of RSV for longer periods of time because RSV surveillance systems have been in operation in some areas for many years. Prevention of RSV infection could not only protect children from the acute effects of the disease but also improve long-term respiratory morbidity, such as recurrent wheezing and asthma [50].

A limitation of our approach is that information collected from middle- and low-income countries is scarce because most of these regions lack RSV surveillance networks. In particular, we acknowledge that certain regions, such as Africa, are under-represented in our analysis. Because the main approach of this review is describing the seasonality of RSV, we did not analyze further epidemiological data, such as transmission patterns or activity of other viral pathogens. Although the effect of climate in the different RSV seasonality patterns was observed in the study for different countries, we did not conduct a deep analysis of this because actual meteorological data were not extracted during the review. It will be interesting to further develop this idea in following analyses. Although most of the surveillance programs do perform sample testing in subjects with symptoms of respiratory infection, those surveillance networks where influenza-like illness is the driver of sampling performance could underestimate RSV epidemic unless influenza and RSV overlap. Finally, circulation of the different RSV subtypes was not further analyzed because almost no surveillance network differentiates between the different genotypes. We decided not to include information in this respect because the literature is based on small sample studies carried out for short periods, preventing a global review of the subject.

In summary, this report provides information that may allow prediction of the beginning of outbreaks of RSV across the world. Even when local epidemic waves are consistent between different years, minor changes between seasons are present from year to year. This variability could turn a prophylactic measure into a useless endeavor if, for example, vaccination campaigns against RSV begin when the outbreak has already started. Therefore, as the data have shown, future seasonal RSV vaccinations campaigns should be organized in line with the different patterns repeated in each region where the program is to be implemented. Although a general dissemination pattern exists for RSV, the described variations from season to season justify introduction of new, well-organized supranational and country- or region-based RSV-specific surveillance tools to predict these variations, as has been done for influenza virus infections in the past. Experience with the influenza virus model has taught us that the effectiveness of efforts directed toward preventive and prophylactic measures would be increased if the seasonal and epidemiological characteristics of the virus waves could be better predicted. Because novel RSV therapeutics are expected to soon become available [20], local seasonality data will allow optimization of the prevention, diagnosis, and treatment of RSV infections.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Financial support. This work was partially supported by a research grant from NOVAVAX, Inc to ReSVinet, which was used to fund part of the field work. F. M. T's research time and activities have been supported by grants from Consellería de Sanidade, Xunta de Galicia, Instituto de Salud Carlos III (Intensificación de la actividad investigadora 2007–2017), Fondo de Investigación Sanitaria (FIS; PI070069/PI1000540/PI1601569) del Plan Nacional de I + D + I and “fondos FEDER,” and 2016-PG071 Consolidación e Estructuración REDES 2016GI-1344 G3VIP (Grupo Gallego de Genética Vacunas Infecciones y Pediatría, ED341D R2016/021). Dr Bont has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (> €100 000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation and MeMed Diagnostics. UMCU has received minor funding participation in trials by Regeneron and Janssen since 2015 (total annual estimate less than €20 000). He received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Janssen (total annual estimate less than €20 000).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. *Pediatr Pulmonol* 2017; 52:556–69.
- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* 2017; 390:946–58.
- Fauroux B, Simões EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. *Infect Dis Ther* 2017; 6:173–97.
- WHO. Global RSV surveillance. *Relevé Epidemiol Hebd* 2016; 91:523–24.

5. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. *Pediatr Infect Dis J* **2003**; 22:S21–32.
6. Haynes AK, Manangan AP, Iwane MK, et al. Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers. *J Infect Dis* **2013**; 208:S246–54.
7. Bloom-Feshbach K, Alonso WJ, Charu V, et al. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. *PLoS One* **2013**; 8:e54445.
8. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España. <http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/gripe.shtml>. Accessed 6 Sep 2017.
9. Public Health England. Annual flu reports. <https://www.gov.uk/government/statistics/annual-flu-reports>. Accessed 6 Sep 2017.
10. Ministry of Health, Israel. Surveillance of influenza-like illness in Israel. https://www.health.gov.il/English/MinistryUnits/ICDC/Infectious_diseases/Flu/Pages/FWR.aspx. Accessed 6 Sep 2017.
11. Australian Government Department of Health. Australian Sentinel Practices Research Network, 1 October to 31 December 2016. <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi4101o.htm>. Accessed 6 Sep 2017.
12. Robertson SE, Roca A, Alonso P, et al. Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. *Bull World Health Organ* **2004**; 82:914–22.
13. Loscertales MP, Roca A, Ventura PJ, et al. Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique. *Pediatr Infect Dis J* **2002**; 21:148–55.
14. Khor CS, Sam IC, Hooi PS, Quek KF, Chan YF. Epidemiology and seasonality of respiratory viral infections in hospitalized children in Kuala Lumpur, Malaysia: a retrospective study of 27 years. *BMC Pediatr* **2012**; 12:32.
15. RKI (Arbeitsgemeinschaft Influenza). Saisonberichte. <https://influenza.rki.de/Saisonbericht.aspx>. Accessed 6 Sep 2017.
16. Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. *J Infect Dis* **1991**; 163:464–9.
17. Gunell M, Antikainen P, Porjo N, et al. Comprehensive real-time epidemiological data from respiratory infections in Finland between 2010 and 2014 obtained from an automated and multianalyte mariPOC® respiratory pathogen test. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* **2016**; 35:405–13.
18. Dirección general de epidemiología. Informe semanal de vigilancia epidemiológica: influenza 2015. http://www.epidemiologia.salud.gob.mx/informes/informesh/2015/docto%20s/influenza/INFLUENZA_2015_SE39.pdf. Accessed 6 Sep 2017.
19. Freitas AR, Donalisio MR. Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations. *Mem Inst Oswaldo Cruz* **2016**; 111:294–301.
20. Centers for Disease Control and Prevention. National Respiratory and Enteric Virus Surveillance System (NREVSS): Respiratory Syncytial Virus (RSV) Surveillance. <https://www.cdc.gov/surveillance/nrevss/rsv/index.html>. Accessed 6 Sep 2017.
21. Australian Government Department of Health. Australian Sentinel Practices Research Network, 2015. <http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi4001j.htm>. Accessed 6 Sep 2017.
22. Hogan AB, Anderssen RS, Davis S, et al. Time series analysis of RSV and bronchiolitis seasonality in temperate and tropical Western Australia. *Epidemics* **2016**; 16:49–55.
23. Paynter S, Ware RS, Sly PD, Weinstein P, Williams G. Respiratory syncytial virus seasonality in tropical Australia. *Aust N Z J Public Health* **2015**; 39:8–10.
24. Ducoffre G, Quoilin S, Wuillaume F. Surveillance of influenza A and respiratory syncytial virus by the Belgian Sentinel Laboratory Network. *Arch Public Health* **2010**; 68:83–4.
25. Houspie L, Lemey P, Keyaerts E, et al. Circulation of HRSV in Belgium: from multiple genotype circulation to prolonged circulation of predominant genotypes. *PLoS One* **2013**; 8:e60416.
26. Zlateva KT, Vijgen L, Dekeersmaeker N, Naranjo C, Van Ranst M. Subgroup prevalence and genotype circulation patterns of human respiratory syncytial virus in Belgium during ten successive epidemic seasons. *J Clin Microbiol* **2007**; 45:3022–30.
27. Raes M, Cox B, Strems D, Nawrot TS. Seasonality of respiratory syncytial virus in Belgium. *Am J Perinatol* **2016**; 33:A024.
28. Lanari M, Giovannini M, Giuffré L, et al; Investigators R.A.D.A.R. Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. *Pediatr Pulmonol* **2002**; 33:458–65.
29. Cangiano G, Nenna R, Frassanito A, et al. Bronchiolitis: analysis of 10 consecutive epidemic seasons. *Pediatr Pulmonol* **2016**; 51:1330–5.
30. Medici MC, Arcangeletti MC, Rossi GA, et al. Four-year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the “Osservatorio VRS” Study (2000–2004). *New Microbiol* **2006**; 29:35–43.
31. Jiménez-Jorge S, Delgado-Sanz C, Mateo S de, et al. Monitoring respiratory syncytial virus through the Spanish

- influenza surveillance system, 2006–2014. *Enferm Infect Microbiol Clin* **2016**; 34:117–20.
32. Cebey-López M, Herberg J, Pardo-Seco J, et al. Viral co-infections in pediatric patients hospitalized with lower tract acute respiratory infections. *PLoS One* **2015**; 10:e0136526.
 33. Sirimi N, Miligkos M, Koutouzi F, Petridou E, Siananidou T, Michos A. Respiratory syncytial virus activity and climate parameters during a 12-year period. *J Med Virol* **2016**; 88:931–7.
 34. Tsolia MN, Kafetzis D, Danelatou K, et al. Epidemiology of respiratory syncytial virus bronchiolitis in hospitalized infants in Greece. *Eur J Epidemiol* **2003**; 18:55–61.
 35. Papadopoulos NG, Moustaki M, Tsolia M, et al. Association of rhinovirus infection with increased disease severity in acute bronchiolitis. *Am J Respir Crit Care Med* **2002**; 165:1285–9.
 36. Prel J-B du, Puppe W, Gröndahl B, et al. Are meteorological parameters associated with acute respiratory tract infections? *Clin Infect Dis Off Publ Infect Dis Soc Am* **2009**; 49:861–68.
 37. Terletskaia-Ladwig E, Enders G, Schalasta G, Enders M. Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study. *BMC Infect Dis* **2005**; 5:20.
 38. Visseaux B, Collin G, Ichou H, et al. Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: a 3 years retrospective study. *PLoS One* **2017**; 12:e0172809.
 39. Gamiño-Arroyo AE, Moreno-Espinosa S, Llamosas-Gallardo B, et al. Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. *Influenza Other Respir Viruses* **2017**; 11:48–56.
 40. Ferrero F, Torres F, Abrutzky R, et al. Seasonality of respiratory syncytial virus in Buenos Aires. Relationship with global climate change. *Arch Argent Pediatr* **2016**; 114:52–5.
 41. Marcone DN, Ellis A, Videla C, et al. Viral etiology of acute respiratory infections in hospitalized and outpatient children in Buenos Aires, Argentina. *Pediatr Infect Dis* **2013**; 32:e105–10.
 42. Otomaru H, Kamigaki T, Tamaki R, et al. Influenza and other respiratory viruses detected by influenza-like illness surveillance in Leyte Island, the Philippines, 2010–2013. *PloS One* **2015**; 10:e0123755.
 43. Suzuki A, Lupisan S, Furuse Y, et al. Respiratory viruses from hospitalized children with severe pneumonia in the Philippines. *BMC Infect Dis* **2012**; 12:267.
 44. Khor CS, Sam IC, Hooi PS, Quek KF, Chan YF. Epidemiology and seasonality of respiratory viral infections in hospitalized children in Kuala Lumpur, Malaysia: a retrospective study of 27 years. *BMC Pediatr* **2012**; 12:32.
 45. Sirirantikorn S, Puthavathana P, Suwanjutha S, et al. Acute viral lower respiratory infections in children in a rural community in Thailand. *J Med Assoc Thai* **2002**; 85:S1167–75.
 46. Park KH, Shin JH, Lee EH, et al. Seasonal variations of respiratory syncytial virus infection among the children under 60 months of age with lower respiratory tract infections in the capital area, the Republic of Korea, 2008–2011. *J Korean Soc Neonatol* **2012**; 19:195.
 47. Zhang Y, Yuan L, Zhang Y, Zhang X, Zheng M, Kyaw MH. Burden of respiratory syncytial virus infections in China: systematic review and meta-analysis. *J Glob Health* **2015**; 5:020417.
 48. Wang H, Zheng Y, Deng J, et al. Prevalence of respiratory viruses among children hospitalized from respiratory infections in Shenzhen, China. *Virol J* **2016**; 13:39.
 49. World Health Organization. WHO technical meeting on piloting RSV surveillance based on the Global Influenza Surveillance and Response System 28–30 June 2016. <http://apps.who.int/iris/bitstream/10665/252617/1/WHO-OHE-PED-GIP-2016.6-eng.pdf?ua=1>. Accessed 6 Sep 2017.
 50. Mazur NI, Martinón-Torres F, Baraldi E, et al; Respiratory Syncytial Virus Network (ReSViNET). Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. *Lancet Respir Med* **2015**; 3:888–900.